Stelara is a monoclonal antibody designed to block the activity ... Agency’s human medicines committee and was based on positive results from the late-stage UNITI-Jr trial, in which 52.1% of ...

STELARA declined 32.3% ... of VERIPULSE in the U.S., the introductions of dual energy STSF in the EU, Velas Uniti, Velas Spine, and Technis Odyssey. Lastly, this slide highlights the one-time ...

Under the Healthcare Common Procedure Coding System (HCPCS), the Q-code Q9999 is for "Injection, for subcutaneous use or intravenous use, ustekinumab-aauz (Otulfi), biosimilar per 1.0 mg." ...

This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab ...

LITTLE ROCK, Ark., April 08, 2025 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that it will report its first quarter 2025 financial results prior to the ...

Fresenius Kabi, an operating company of Fresenius, announced that the Centers for Medicare and Medicaid Services issued a permanent, product-specific billing code for Otulfi (ustekinumab-aauz).

LITTLE ROCK, Ark., April 23, 2025 (GLOBE NEWSWIRE) -- Uniti Group Inc. ("Uniti” or the "Company”) (Nasdaq: UNIT) today announced its appointment of John Harrobin as President of Kinetic, effective ...

Among the most significant milestones was the launch of ustekinumab biosimilars following the loss of exclusivity for Stelara. This expansion has played a pivotal role in fostering market ...

Jennifer Banner Recognized for Her 10 Years of Dedicated Service LITTLE ROCK, Ark., April 17, 2025 (GLOBE NEWSWIRE) -- Uniti Group Inc. ("Uniti” or the "Company”) (Nasdaq: UNIT) today announced that ...